AbleDocs Inc. Announces the Acquisition of Diversa Docs ApS to Further the Reach of the Worldwide Leader in Document Accessibility Products and Services Throughout Scandinavia
6.4.2021 15:42:00 EEST | Business Wire | Press release
AbleDocs Inc. the leading PDF accessibility product and service provider, and Diversa Docs ApS, a recognized leader in PDF and Web Accessibility services announce their coming together to become the Scandinavian leader in PDF accessibility products and services.
With a long-standing record of collaboration, both companies’ founders and leadership teams couldn’t be more excited to leverage each other’s capabilities to offer their existing and new clients the best in PDF/UA products and services.
“Diversa Docs has consistently been recognized as a leader in excellence in delivering PDF/UA compliant and accessible PDFs, and this acquisition will allow our combined client base to benefit from the experience, and scale of our products and services throughout Scandinavia,” said AbleDocs’ President (GLOBAL), Adam Spencer. “With their amazing team and end user focused approach, they are the ideal partner for AbleDocs. With our combined effort, we can drive the creation of next-generation PDF accessibility services and solutions,” said Vice-President (SCANDINAVIA), Jens Bjerre Kirkegaard.
“Accessibility has always appealed to me because it combines a technical field with a humanistic one,” says CEO of Diversa Docs, Asbjørn Fangel-Hansen.
“Having worked for 12 years in the Danish public sector within accessibility and most recently as the owner of one of the leading companies in the field of accessibility in Denmark, I am very honored to be part of one of the absolute leading global players when it comes to accessible documents,” adds Fangel-Hansen.
The combination of AbleDocs and Diversa Docs will widen the global presence of AbleDocs for products, services, solution development, training, and localized document accessibility support across 49 languages to ensure clients receive the best offerings possible.
About Diversa Docs
Diversa Docs ApS was founded by Lars Holm-Sørensen and Asbjørn Fangel-Hansen in 2019 as a sister company to Diversa ApS. Since then, the company has developed into one of the leaders in Denmark in terms of document accessibility and the area in general.
About AbleDocs Inc.
AbleDocs was founded in 2019 as a conglomerate of PDF accessibility remediation service providers and has grown to have operations in Canada, Denmark, Germany, Switzerland, and the United States. Its founders have been making documents accessible for over 150 years combined experience and has since expanded its offerings to include a completely new approach to document accessibility strategies to include products for high volume document accessibility, document accessibility testing.
AbleDocs is the only company in the world to guarantee the compliance of every file they produce and back it with a $10,000,000 liability guarantee. Current offerings include ADService, ADGateway, ADScan, ADStream, ADLegacy, ADForms, axesWord and axesPDF.
For more information, visit https://www.abledocs.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210406005229/en/
Contact information
For media inquiries:
Gary MacKay, mediainquiries@abledocs.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 12:47:00 EEST | Press release
Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food products. Within this inspiring premise, Good Food Makers confirms itself as one of the main levers f
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 11:16:00 EEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom